Scpharmaceuticals Stock Investor Sentiment
| SCPH Stock | USD 5.18 0.08 1.52% |
Under 60% of Scpharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Scpharmaceuticals stock suggests that many investors are alarmed at this time. Scpharmaceuticals' investing sentiment shows overall attitude of investors towards Scpharmaceuticals.
Scpharmaceuticals |
Scpharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Scpharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Scpharmaceuticals that are available to investors today. That information is available publicly through Scpharmaceuticals media outlets and privately through word of mouth or via Scpharmaceuticals internal channels. However, regardless of the origin, that massive amount of Scpharmaceuticals data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Scpharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Scpharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Scpharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Scpharmaceuticals alpha.
Scpharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Veitinger Klaus R Dr of 19750 shares of Scpharmaceuticals at 4.11 subject to Rule 16b-3 | 07/17/2024 |
2 | Disposition of 10445 shares by Rachael Nokes of Scpharmaceuticals at 1.66 subject to Rule 16b-3 | 08/06/2024 |
3 | scPharmaceuticals Announces Positive Topline Study Results for SCP-111 Autoinjector | 08/12/2024 |
4 | Acquisition by Orbimed Advisors Llc of 21658 shares of Scpharmaceuticals at 4.0 subject to Rule 16b-3 | 08/13/2024 |
5 | scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update | 08/14/2024 |
6 | scPharmaceuticals Inc Q2 2024 Earnings Call Transcript Highlights Strong Revenue Growth ... | 08/15/2024 |
7 | scPharmaceuticals Second Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 08/16/2024 |
8 | Disposition of 6124 shares by Schaeffer Leonard D of Scpharmaceuticals at 3.37 subject to Rule 16b-3 | 08/26/2024 |
9 | Acquisition by Rachael Nokes of 10445 shares of Scpharmaceuticals at 1.66 subject to Rule 16b-3 | 08/28/2024 |
10 | Acquisition by John Tucker of 100000 shares of Scpharmaceuticals subject to Rule 16b-3 | 08/30/2024 |
11 | Acquisition by Rachael Nokes of 85750 shares of Scpharmaceuticals subject to Rule 16b-3 | 09/03/2024 |
12 | Investors in scPharmaceuticals have unfortunately lost 23 percent over the last year | 09/16/2024 |
Complementary Tools for Scpharmaceuticals Stock analysis
When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |